© 1999 by European Society of Cardiology
Determinants of development of permanent atrial fibrillation and its treatment
aArrhythmologic Center Ospedali Riuniti, Lavagna; bArrhythmologic Center Ospedale S Maria Nuova, Reggio Emilia, Italy
We evaluated the rate of progression of permanent atrial fibrillation (AF) and identified clinical factors that predict this event in 63 consecutive patients who had undergone AV junctional ablation and DDDR pacemaker implantation for drug-refractory paroxysmal atrial fibrillation/flutter. Immediately after ablation, anti-arrhythmic drugs were discontinued in all cases. Permanent AF was con-sidered to have developed if AF was present on two consecutive 6-monthly examinations with no interim documented sinus rhythm. During a mean follow-up of 23±16 months, 22 (35%) of the 63 patients developed permanent AF. The actuarial estimate of progression of permanent AF was 22%, 40% and 56%, respectively, 1, 2 and 3 years after ablation. Age and underlying heart disease were independent predictors of progression of permanent AF. Only one (6%) of 16 patients with idiopathic AF had permanent AF (low risk group). Among the 47 patients with structural heart disease, permanent AF developed in 18 (62%) of the 29 who were aged >75 years or had >12 arrhythmic episodes per year and a symptom duration >4 years (high risk group), but only in three (17%) of the remaining 18 patients who did not (intermediate risk group). In conclusion, during a 3-year follow-up period, about half of the patients with a history of drug-refractory paroxysmal AF did not develop permanent AF after AV junctional ablation and dual-chamber pacemaker implantation, even in the absence of anti-arrhythmic drug therapy. Moreover, subgroups of patients whose risk of permanent AF progression differed were identified on the basis of simple baseline clinical variables. The results of this study form the necessary background for the correct management of patients after AV junction ablation and for the planning of future trials in this field.
Key Words: Catheter ablation, dual-chamber pacemaker, paroxysmal atrial fibrillation, natural history of atrial fibrillation, atrioventricular junctional ablation
Correspondence: Michele Brignole, MD, Via A Grilli 164, 16041 Borzonasca (GE), Italy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A Queiroga, H J Marshall, M Clune, and M D Gammage Ablate and pace revisited: long term survival and predictors of permanent atrial fibrillation Heart, September 1, 2003; 89(9): 1035 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brignole, M. Gammage, L. Jordaens, R. Sutton, and on behalf of the Barcelona Discussion Group Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation Europace, January 1, 1999; 1(1): 8 - 13. [Abstract] [PDF]
|
|